Wrapping up Q4 earnings, we look at the numbers and key takeaways for the testing & diagnostics services stocks, including NeoGenomics (NASDAQ:NEO) and its peers.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the healthcare providers & services industry, including AMN Healthcare Services (NYSE:AMN) and its peers.
Looking back on testing & diagnostics services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Labcorp (NYSE:LH) and its peers.
RadNet has gotten torched over the last six months - since September 2024, its stock price has dropped 25.7% to $51.34 per share. This may have investors wondering how to approach the situation.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q4, starting with RadNet (NASDAQ:RDNT).
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Quest (NYSE:DGX) and the best and worst performers in the testing & diagnostics services industry.
Diagnostic imaging company RadNet (NASDAQ:RDNT) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 13.5% year on year to $477.1 million. On the other hand, the company’s full-year revenue guidance of $1.94 billion at the midpoint came in 1.2% below analysts’ estimates. Its GAAP profit of $0.07 per share was 40.7% below analysts’ consensus estimates.
